Browse News
Filter News
Found 874 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
DNA Nanotechnology Market Expected to Grow at a CAGR of 24.67% from 2024 to 2031
4/22/2024
Global DNA Nanotechnology Market is valued at US$ 4.34 Bn in 2023, and it is expected to reach US$ 24.29 Bn by 2031, with a CAGR of 24.67% during the forecast period of 2024-2031.
-
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
4/15/2024
INOVIO Pharmaceuticals, Inc. announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share and pre-funded warrants to purchase 2,135,477 shares of its common stock at an offering price of $7.692 per pre-funded warrant, in each case before underwriting discounts and commissions.
-
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
3/26/2024
INOVIO announced that Dr. Jacqueline Shea, President and CEO will participate in The Novel Therapeutics Forum hosted by Citizens JMP at Penn Medicine at 10:00 am ET on April 2, 2024.
-
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
3/13/2024
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for its fiscal fourth quarter and full year ended December 31, 2023 and recent business highlights.
-
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
3/6/2024
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the fourth quarter and full year ended December 31, 2023.
-
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
2/21/2024
INOVIO today announced that fourth quarter and year-end 2023 financial results will be released after the market close on March 6, 2024.
-
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/7/2024
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.
-
INOVIO Reports Inducement Grant Under Inducement Plan
2/2/2024
INOVIO today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
-
INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split
1/23/2024
INOVIO today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock will be effective as of 5:00 p.m.
-
INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader
1/22/2024
INOVIO today announced that it will participate in a virtual fireside chat on the potential treatment of Recurrent Respiratory Papillomatosis (RRP).
-
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
1/4/2024
INOVIO today announced a clinical collaboration and supply agreement with Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) to evaluate the combination of INO-3112 and LOQTORZI.
-
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program
1/3/2024
INOVIO today announced plans to submit a BLA for INO-3107 as a potential treatment for Recurrent Respiratory Papillomatosis (RRP) in the second half of 2024.
-
enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors
12/19/2023
enGene Holdings Inc. today announced the appointment of Lota S. Zoth, CPA, as a member of the Board of Directors and Audit Committee Chair.
-
INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights
11/9/2023
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2023.
-
INOVIO Reports Inducement Grants Under Inducement Plan - November 1, 2023
11/1/2023
INOVIO today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan.
-
INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023
10/26/2023
INOVIO today announced that third quarter 2023 financial results will be released after the market close on November 9, 2023.
-
INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program
10/10/2023
INOVIO today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) that data from its completed Phase 1/2 trial of INO-3107 for the treatment of RRP could support INOVIO's submission of a BLA for review under the FDA's accelerated approval program.
-
Maravai LifeSciences Chief Innovation Officer Kate Broderick Named to 2023 PharmaVoice 100
9/19/2023
Maravai LifeSciences, Inc. announced that Chief Innovation Officer Kate Broderick, PhD, has been named to the 2023 PharmaVoice 100 list, which recognizes the most inspiring leaders in the life sciences.
-
INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
9/7/2023
INOVIO today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for INO-3107 as a potential treatment for patients with Recurrent Respiratory Papillomatosis (RRP).